Clostridium difficile drug pipeline: challenges in discovery and development of new agents

Journal of Medicinal Chemistry
Angie M JarradMatthew A Cooper

Abstract

In the past decade Clostridium difficile has become a bacterial pathogen of global significance. Epidemic strains have spread throughout hospitals, while community acquired infections and other sources ensure a constant inoculation of spores into hospitals. In response to the increasing medical burden, a new C. difficile antibiotic, fidaxomicin, was approved in 2011 for the treatment of C. difficile-associated diarrhea. Rudimentary fecal transplants are also being trialed as effective treatments. Despite these advances, therapies that are more effective against C. difficile spores and less damaging to the resident gastrointestinal microbiome and that reduce recurrent disease are still desperately needed. However, bringing a new treatment for C. difficile infection to market involves particular challenges. This review covers the current drug discovery pipeline, including both small molecule and biologic therapies, and highlights the challenges associated with in vitro and in vivo models of C. difficile infection for drug screening and lead optimization.

References

Sep 1, 1978·The Journal of Antimicrobial Chemotherapy·E J Baines
May 15, 1992·Journal of Medicinal Chemistry·A J CorrazC C Wei
Jun 1, 1991·Antimicrobial Agents and Chemotherapy·R N SwansonJ J Clement
Jul 1, 1991·Antimicrobial Agents and Chemotherapy·T TerasawaS Mitsuhashi
Oct 1, 1990·The Journal of Antibiotics·Y TeruiJ Shoji
Dec 1, 1989·The Journal of Antibiotics·J ShojiT Yoshida
Mar 1, 1995·Antimicrobial Agents and Chemotherapy·D A BeauregardD J Knowles
Aug 1, 1993·Diagnostic Microbiology and Infectious Disease·J SegretiG M Trenholme
Aug 6, 1993·Journal of Medicinal Chemistry·R J TernanskyJ S Kasher
Mar 1, 1993·The Journal of Antibiotics·J E McCulloughP B Fernandes
Feb 1, 1993·The Journal of Antimicrobial Chemotherapy·D I Edwards
May 21, 1998·Antimicrobial Agents and Chemotherapy·P C FuchsS D Brown
Apr 2, 1999·Antimicrobial Agents and Chemotherapy·Y GeM Zasloff
Jul 30, 1999·Journal of Medicinal Chemistry·Y KatsuraH Takasugi
Jul 18, 2000·Antimicrobial Agents and Chemotherapy·Z D JiangH Dupont
Aug 15, 2000·Annual Review of Biophysics and Biomolecular Structure·P J Loll, P H Axelsen
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·C S McVay, R D Rolfe
Sep 12, 2000·The Journal of Antimicrobial Chemotherapy·K TanakaK Watanabe
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Michael J PucciYasutsugu Ueda
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Pauline M AntonCharalabos Pothoulakis
Nov 25, 2004·Antimicrobial Agents and Chemotherapy·Sydney M FinegoldMauricio Bolaños
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jacques PepinClaude Bourassa
Dec 3, 2005·The New England Journal of Medicine·L Clifford McDonaldDale N Gerding
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald P Levine
Jul 31, 2007·Journal of Microbiological Methods·John T HeapNigel P Minton
Feb 5, 2008·Bioorganic & Medicinal Chemistry Letters·Cait CostelloTony Worthington
Jun 19, 2008·Antimicrobial Agents and Chemotherapy·Jennifer R O'ConnorStuart Johnson
Jul 18, 2008·Bioorganic & Medicinal Chemistry Letters·Joseph I AmbrusKim Lewis
Jul 25, 2008·Journal of Clinical Microbiology·T PeláezE Bouza

❮ Previous
Next ❯

Citations

Dec 17, 2015·Journal of Industrial Microbiology & Biotechnology·Victoria Knight-ConnoniJared Silverman
Jan 31, 2016·Advanced Drug Delivery Reviews·Elena MorozJean-Christophe Leroux
Jun 29, 2015·European Journal of Medicinal Chemistry·Angie M JarradMatthew A Cooper
Mar 5, 2016·Expert Opinion on Investigational Drugs·Lynne V McFarland
May 14, 2016·Expert Opinion on Drug Discovery·Alastair L Parkes, Ian A Yule
Sep 17, 2016·Scientific Reports·Major Gooyit, Kim D Janda
Sep 24, 2016·Journal of Clinical Medicine·Eamonn P Culligan, Roy D Sleator
Feb 11, 2016·Therapeutic Advances in Infectious Disease·Patrizia Spigaglia
Mar 31, 2017·Organic & Biomolecular Chemistry·Qingfei ZhengWen Liu
Mar 24, 2016·World Journal of Gastroenterology : WJG·Lynne Vernice McFarlandShan Goh
Apr 17, 2020·Frontiers in Genetics·Dmitrii Y TravinKonstantin Severinov
Mar 30, 2020·Scientific Reports·Chandradhish GhoshJayanta Haldar
Jan 1, 2015·Antibiotics·Eric WenzlerLarry H Danziger
Mar 7, 2020·The Journal of Antibiotics·Ahmed AbdelKhalekMohamed N Seleem
Jan 27, 2021·Drug Discovery Today·Alessandra T ZizzariRainer Riedl
Nov 17, 2019·Current Opinion in Microbiology·Matthew I HutchingsBarrie Wilkinson
May 18, 2021·Therapeutic Advances in Gastroenterology·Abdelkader Chaar, Paul Feuerstadt
May 22, 2021·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·James FlynnSarah P Hudson
May 4, 2017·Journal of Medicinal Chemistry·Chee Wei AngMark A T Blaskovich

❮ Previous
Next ❯

Methods Mentioned

BETA
chemical modifications
gene-knockout

Software Mentioned

ClosTron
Reaxys
Microbiotix
Biota
Pipeline Pilot
Rebiotix
ChEMBL
ViroPharma

Related Concepts

Related Feeds

Bacteriotherapy (ASM)

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Bacteriotherapy

Bacteriotherapy, also known as fecal transplantation, involves the transfer of stool from a healthy donor into the gastrointestinal tract for the purpose of treating recurrent C. difficile colitis. Here is the latest on bacteriotherapy.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Kate Traynor
The New England Journal of Medicine
Amy LinskyJohn A Hermos
The New England Journal of Medicine
Nasia Safdar, William A Craig
© 2021 Meta ULC. All rights reserved